FDA Approves Opdivo for Hard-to-Treat Hodgkin Lymphoma
By Hope Cristol Patients with hard-to-treat Hodgkin lymphoma now have a new treatment option. The U.S. Food and Drug Administration granted accelerated approval to Opdivo (nivolumab) for classic Hodgkin lymphoma that has returned or progressed after a specific type of stem cell transplant and post-transplant medicine. Hodgkin lymphoma is a cancer of the lymph system, which is part of the immune system. There are two main types of this disease, but “classic” Hodgkin lymphoma accounts for about 95% of all cases in developed countries. The American Cancer Society estimates about 8,500 new cases of Hodgkin lymphoma will be diagnosed in 2016, with a 5-year survival rate ranging from 90% for stage I to 65% for stage IV. When Hodgkin lymphoma comes back after treatment (relapsed disease) or doesn’t go away after treatment (refractory disease), the next step is often an autologous stem cell transplant. This treatment uses high doses of chemotherapy, followed by reinfusing a patients’ own blood and marrow stem cells back into the body. The anticancer drug Adcetris (brentuximab vedotin) may be given to patients post-transplant. Opdivo, an immunotherapy drug, can now be used for Hodgkin lymphoma if these treatments don’t work. In clinical trials that formed the basis of the new approval, 95 patients with relapsed or refractory disease were treated with Opdivo. It was found to shrink tumors in 65% of patients: 58% achieved partial remission and 7% achie...
This study investigated the presence of Streptococci, Staphylococci, aerobic gram negative bacteria (AGNB), Candida and bacterial endotoxins in the oral cavities of patients receiving chemo- and/or radiotherapy for cancer.MethodsSamples of oral cavity rinse were collected from 100 patients on cancer treatment and 70 healthy individuals. Demographic and clinical data were recorded. Samples were cultured onto various agar plates for qualitative and quantitative analysis and tested for the presence of endotoxin. Results were analysed using the Mann-Whitney and chi-square tests.ResultsIn cancer patients, S. aureus counts were ...
Publication date: Available online 18 July 2018Source: Best Practice &Research Clinical HaematologyAuthor(s): H. Miles Prince, Christiane QuerfeldAbstractNovel systemic therapies are generally prescribed to patients with advanced-stage disease or those with early-stage disease refractory to skin-directed therapies. In general, systemic chemotherapy should be reserved for patients who fail to respond to biological agents. Such biological agents include interferon alfa, bexarotene, histone deacetylase inhibitors (vorinostat, romidepsin), brentuximab vedotin and mogamulizumab. Extracorporeal photopheresis is particularly ...
AbstractLow molecular weight heparins (LMWHs) are considered the standard of care for the treatment of venous thromboembolism (VTE) associated with cancer. We conducted a meta-analysis to evaluate the safety and efficacy of direct oral anticoagulants (DOACs) in patients with cancer. We systematically searched Medline for potential randomized-control clinical trials (RCTs) and post-hoc analyses. For each study, data on recurrent VTE, major or clinically relevant non-major bleeding (CRNMB), and major bleeding (MB) were extracted. Initially, a total of 1395 citations were identified. Eight studies met our eligibility criteria...
Publication date: Available online 21 February 2018Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAuthor(s): Manoela S. Pereira, Vivian P. Wagner, Maria Cristina Munerato, Nadine O. Clausell, Livia A. Goldraich, Marco Antonio T. Martins, Manoela D. Martins, Vinicius C. Carrard
Publication date: Available online 8 February 2018Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAuthor(s): Brian M. Will, Scott M. Peters, Sidney B. Eisig, John T. Grbic, Michael A. McKenzie, Angela J. Yoon, Elizabeth M. Philipone
ConclusionsThe expression of both cyclin D1 and p27KIP1 correlated with the grade of oral epithelial dysplasia and degree of OSCC differentiation. The results obtained will be verified through a basic follow-up of the cases to determine the prognosis/progression of oral dysplasia.
ConclusionsIg clonal gene rearrangements assays using BIOMED-2 protocol can be a highly reliable diagnostic method for parotid gland MALT lymphoma. For patients with Sjögren syndrome along with histologically benign lymphoepithelial lesion, identification of Ig clonal gene rearrangements is important for routine differential diagnosis.
ConclusionOMF ALL/LBL is rare, but its microscopic features and immunohistochemical profiles CD3+or CD79 a+/CD10+/CD34+variable/CD99+/TdT+ contribute to the correct diagnosis.
ConclusionsWe conclude that the reconstruction of TMJ surfaces by matrix-associated chondrocyte transplantation may become a routine method for cartilage regeneration in the TMJ in the future.
ConclusionsBilateral mandibular osteoradionecrosis can be managed with virtual surgical planning, and the defects can be reconstructed using 2 separate flaps prepared from a single fibula.
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Food and Drug Administration (FDA) | Hodgkin's Disease | Immunotherapy | Kidney Cancer | Kidney Transplant | Kidney Transplantation | Lung Cancer | Lung Transplant | Lymphoma | Melanoma | Non-Small Cell Lung Cancer | Respiratory Medicine | Skin Cancer | Stem Cell Therapy | Stem Cells | Study | Transplant Surgery | Transplants | Urology & Nephrology